Literature DB >> 1771258

Radical surgery and postoperative split-course radiotherapy in squamous cell carcinoma of the mobile tongue: factors influencing local control and the time to recurrence.

M Kajanti1, L R Holsti, P Holsti.   

Abstract

During 1981-1988 63 patients with squamous cell carcinoma of the oral tongue (27 females and 36 males) were treated with radical surgery and postoperative split-course radiotherapy. The 3-week rest period was compensated with a 10% increase in the total radiation dose to 66 Gy. The local control rate was 76% in stage I, 71% in stage II, 45% in stage III and 0% in stage IV. Failures were observed in 25 (40%) patients, and 8 patients died of intercurrent diseases. For further analysis the material was stratified in three groups according to the time interval between surgery and postoperative radiotherapy: less than 6 weeks, 6-8 weeks and greater than 8 weeks. The local control rate in the three strata were 75, 57 and 44%, and the 5-year actuarial survival 61, 46 and 30%, respectively. In the logistic regression analysis and the proportional hazard's regression analysis the histologic grade of the primary tumour and the time interval between surgery and the start of radiotherapy were the most important factors influencing respectively local control and time to recurrence. However, it appeared that the lengthening of the time interval was often caused by factors or events which directly can influence the prognosis, such as surgical complications, infections and poor general condition. When cases with such special causes for lengthening of the interval were excluded, the effect of the time interval nearly completely disappeared. It would seem that a final evaluation of the effect of the time interval requires a prospective randomized trial. The same may well hold true for reliable evaluation of the influence of overall treatment time.

Entities:  

Mesh:

Year:  1991        PMID: 1771258     DOI: 10.1016/0167-8140(91)90021-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies.

Authors:  Arash O Naghavi; Michelle I Echevarria; G Daniel Grass; Tobin J Strom; Yazan A Abuodeh; Kamran A Ahmed; Youngchul Kim; Andy M Trotti; Louis B Harrison; Kosj Yamoah; Jimmy J Caudell
Journal:  Cancer       Date:  2016-08-01       Impact factor: 6.860

Review 2.  [Delays and treatment interruptions: difficulties in administering radiotherapy in an ideal time-period].

Authors:  Carmen González San Segundo; Felipe A Calvo Manuel; Juan Antonio Santos Miranda
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

3.  Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database.

Authors:  Deborah T Blumenthal; Minhee Won; Minesh P Mehta; Walter J Curran; Luis Souhami; Jeff M Michalski; C Leland Rogers; Benjamin W Corn
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

4.  Association of Survival With Shorter Time to Radiation Therapy After Surgery for US Patients With Head and Neck Cancer.

Authors:  Jeremy P Harris; Michelle M Chen; Ryan K Orosco; Davud Sirjani; Vasu Divi; Wendy Hara
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-04-01       Impact factor: 6.223

5.  The impact of the interval between the induction of chemotherapy and radiotherapy on the survival of patients with nasopharyngeal carcinoma.

Authors:  Shiping Yang; Xiaoling Fu; Guang Huang; Junni Chen; Shishi Luo; Zhenping Wang; Fanzhong Kong; Gang Wu; Shaomin Lin; Fen Wang; Longhua Chen
Journal:  Cancer Manag Res       Date:  2019-03-22       Impact factor: 3.989

6.  Ultrasound-guided microwave ablation in the treatment of early-stage tongue cancer.

Authors:  Jianquan Yang; Wen Guo; Rong Huang; Zhengmin Xu; Chunyang Zhou; Man Lu
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.